Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Prasugrel
Drug ID BADD_D01822
Description Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.
Indications and Usage Indicated in combination with acetylsalicylic acid (ASA) to prevent atherothrombotic events in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI). May be used in patients with unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI), ST-elevation myocardial infarction (STEMI) who are to be managed with PCI. Prasugrel is not recommended in patients 75 years of age or greater, those that weigh<60kg, and patients with a history of stroke or transient ischemic attack due to increased risk of fatal and intracranial bleeding.
Marketing Status approved
ATC Code B01AC22
DrugBank ID DB06209
KEGG ID D05597
MeSH ID D000068799
PubChem ID 6918456
TTD Drug ID D07IRF
NDC Product Code 43817-240; 51407-444; 0378-5185; 65862-829; 43817-239; 50090-5169; 65162-002; 66003-602; 66003-601; 60505-4643; 16729-272; 0378-5186; 65162-001; 65862-830; 14501-0084; 51407-445; 60505-4642; 16729-273
UNII 34K66TBT99
Synonyms Prasugrel Hydrochloride | Hydrochloride, Prasugrel | Prasugrel HCl | HCl, Prasugrel | CS 747 | 747, CS | CS-747 | CS747 | Prasugrel | Efient | Effient | LY 640315 | 640315, LY | LY640315 | LY-640315
Chemical Information
Molecular Formula C20H20FNO3S
CAS Registry Number 150322-43-3
SMILES CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Puncture site haemorrhage24.07.01.034; 12.07.04.006; 08.02.04.007--Not Available
Large intestine polyp16.05.02.006; 07.20.01.0100.000846%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.0150.000384%Not Available
Lymphatic disorder01.09.01.003--Not Available
Large intestinal haemorrhage24.07.02.026; 07.12.03.0030.000384%
Cerebral haematoma17.08.01.014; 24.07.04.0060.000384%Not Available
Haemorrhage24.07.01.0020.012761%Not Available
Haemobilia24.07.01.049; 09.01.08.0090.000577%Not Available
Angiopathy24.03.02.007--Not Available
Drug resistance08.06.01.0050.001038%Not Available
Adverse event08.06.01.0100.001422%Not Available
Cardiac disorder02.11.01.0030.000384%Not Available
Intra-abdominal haemorrhage24.07.02.035; 12.01.17.011; 07.12.02.0080.000384%
Ischaemic stroke24.04.06.010; 17.08.01.0180.000961%Not Available
Mediastinal disorder22.09.03.001--Not Available
Colorectal cancer16.13.01.002; 07.21.01.002--Not Available
Blood disorder01.05.01.004--Not Available
Drug intolerance08.06.01.0130.002614%Not Available
Hyperlipidaemia14.08.03.001--
Non-cardiac chest pain08.01.08.006; 22.12.02.0090.001422%
Vascular stent thrombosis24.01.01.044; 08.07.05.0020.002306%Not Available
Vessel puncture site haematoma24.07.01.018; 12.07.04.003; 08.02.04.002--Not Available
Treatment failure08.06.01.0170.000577%Not Available
Acute kidney injury20.01.03.0160.001153%
Drug-induced liver injury12.03.01.044; 09.01.07.0230.000384%Not Available
Cerebellar haemorrhage24.07.04.023; 17.08.01.0460.000384%Not Available
Dressler's syndrome22.05.01.005; 10.04.04.014; 02.06.01.0080.000384%Not Available
Ruptured cerebral aneurysm24.02.04.005; 17.08.01.0590.000577%Not Available
Obstructive shock24.06.02.024; 02.05.01.0130.000384%Not Available
Vascular stent stenosis24.04.02.028; 08.07.05.0070.001537%Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages